Experimental Zika vaccine to begin human testing
WASHINGTON - An experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.
Inovio Pharmaceuticals said Monday that it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus.
The company's vaccine is intended to prime the immune system to fight Zika by introducing genetically-engineered materials that resemble the virus. Inovio reports that animals tested with the vaccine developed antibodies and other cells that attack Zika.
Inovio and its partner, GeneOne Life Science, plan to begin a 40-person study to determine the safest dose of the vaccine in coming weeks.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Meeting about future of Capitol High brings more questions than answers
Fish Bayou flood control project wrapping up; Alligator Bayou Road soon to...
Comite Diversion completion date now at the end of 2025
United Way receives overwhelming amount of applicants for utility assistance
Months after deputies raided police department, missing money suddenly found in evidence...
WATCH: LSU QB Garrett Nussmeier talks to media about fall camp
WATCH: LSU QB Jayden Daniels talks fall camp
LSU QB Myles Brennan quitting football, not at practice Monday morning
Sports2's 1-on-1 with 5 star LSU commit Shelton Sampson
WATCH: 1-on-1 with recent LSU commit QB Rickie Collins